{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:20Z","timestamp":1790289500716,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The efficacy and prognostic value of circulating tumor cells (CTCs) in nonsmall cell lung cancer (NSCLC) are controversial based on the existing research. This systematic review and meta\u2010analysis evaluated the significance of CTCs in NSCLC therapy monitoring and prognosis prediction, supporting their potential as clinical biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a comprehensive search of PubMed, Embase, Web of Science, The Cochrane Library, WanFang Data, CNKI, and VIP through September 20, 2023. Inclusion criteria were cohort studies involving NSCLC patients, focusing on peripheral blood CTCs, and assessing outcomes such as pre\u2010 and posttreatment CTC rates or levels, progression\u2010free survival (PFS), and overall survival (OS). Two reviewers independently extracted the data and assessed risk of bias using the Newcastle\u2010Ottawa Scale. We utilized Review Manager 5.4.1 for meta\u2010analysis, calculating pooled odds ratios (ORs) for dichotomous outcomes, mean differences for continuous variables and hazard ratios (HRs) for survival data, applying fixed\u2010 or random\u2010effects models based on heterogeneity assessed by the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistic. This study was registered in PROSPERO (No. CRD42023450035).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty\u2010two eligible studies with a total of 1674 NSCLC patients were included. Meta\u2010analysis results showed that the CTCs\u2010positive rate (OR\u00a0=\u00a00.59, 95% CI 0.45 to 0.77, <jats:italic>p\u00a0=\u00a0<\/jats:italic>0.0001) and CTCs count (mean difference\u00a0=\u00a0\u20133.10, 95% CI \u20135.52 to \u20130.69, <jats:italic>p\u00a0=\u00a0<\/jats:italic>0.01) were significantly decreased after antitumor treatment. Compared with the CTCs nonreduced group, the CTC\u2010reduced group showed better PFS (HR\u00a0=\u00a01.71, 95% CI 1.35 to 2.17, <jats:italic>p\u00a0<\/jats:italic>&lt;\u00a00.00001) and OS (HR\u00a0=\u00a01.50, 95% CI 1.21 to 1.86, <jats:italic>p\u00a0=\u00a0<\/jats:italic>0.0003) after treatment. PFS and OS in CTC\u2010positive groups were lower than those in the CTCs\u2010negative group pretreatment (HR\u00a0=\u00a02.49, 95% CI 1.78 to 3.47, <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.00001; HR\u00a0=\u00a01.80, 95% CI 1.29 to 2.52, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.0006) and posttreatment (HR\u00a0=\u00a03.36, 95% CI 2.12 to 5.33, <jats:italic>p\u00a0<\/jats:italic>&lt;\u00a00.00001; HR\u00a0=\u00a03.31, 95% CI 1.75 to 6.27, <jats:italic>p\u00a0=\u00a0<\/jats:italic>0.0002).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CTCs can be used as a biomarker to monitor NSCLC efficacy, predict prognosis and guide follow\u2010up treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jebm.12606","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T05:34:12Z","timestamp":1712813652000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The detection of circulating tumor cells indicates poor therapeutic efficacy and prognosis in patients with nonsmall cell lung cancer: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"17","author":[{"given":"Shan","family":"Wang","sequence":"first","affiliation":[{"name":"Cancer Center, Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Lv","sequence":"additional","affiliation":[{"name":"Cancer Center, Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9521-261X","authenticated-orcid":false,"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Cancer Center, Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Center, Beijing Friendship Hospital Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.001"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S17191"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.08.012"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-2-s41"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2016.01.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.11.003"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.02.024"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254433"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-590"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1832"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-013-1128-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219129"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-013-1592-3"},{"issue":"4","key":"e_1_2_7_18_1","first-page":"1077","article-title":"Circulating tumor cells predict prognosis following secondline AZD 9291 treatment in EGFR\u2010T790M mutant non\u2010small cell lung cancer patients","volume":"23","author":"Yang B","year":"2018","journal-title":"J buon"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.10.003"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0649-2"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051035"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00455.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28975"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504012X13473664562583"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.7045"},{"issue":"5","key":"e_1_2_7_29_1","first-page":"879","article-title":"Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non\u2010small cell lung cancer (NSCLC)","volume":"8","author":"Liang S","year":"2018","journal-title":"Am J Cancer Res"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3148"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3727\/096504017X14928634401178"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx156"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6010153"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S144033"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21255"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12696"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3269-x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0445"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-160090"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82068-9"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078070"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-1029-x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0151-2022"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1329"},{"issue":"24","key":"e_1_2_7_45_1","first-page":"12735","article-title":"Effect of CTCs and INHBA level on the effect and prognosis of different treatment methods for patients with early breast cancer","volume":"24","author":"Wang XQ","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1228522"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.019"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3733"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.802188"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.023"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy172"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23488"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12901"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prosdent.2013.11.012"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1695"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00207"}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.12606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T17:36:27Z","timestamp":1738431387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jebm.12606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/jebm.12606"],"URL":"https:\/\/doi.org\/10.1111\/jebm.12606","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}